Eye News and Research

Latest Eye News and Research

Study reports ROP18 protein protects parasite in host cell

Researchers at Washington University School of Medicine in St. Louis have learned why changes in a single gene, ROP18, contribute substantially to dangerous forms of the parasite Toxoplasma gondii. The answer has likely moved science a step closer to new ways to beat Toxoplasma and many other parasites.

28 Dec 2010

Alimera receives FDA CRL for ILUVIEN NDA

pSivida Corp., a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, including the investigational drug ILUVIEN® for the treatment of Diabetic Macular Edema (DME), today announced that Alimera Sciences, Inc, pSivida's collaborative partner, received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for ILUVIEN. The FDA issued the CRL to communicate its decision that the NDA cannot be approved in its present form.

24 Dec 2010

Health spending and mandates: What is central to the overhaul's implementation and what is not

CQ looks forward and offer analyses regarding how determinations about mandatory and discretionary spending will impact the health law's implementation. Meanwhile, Modern Healthcare reports on a new study exploring how central the individual insurance mandate is to expanding coverage.

24 Dec 2010

Santen files IND for Clinical Data's ATL313 for primary open angle glaucoma and ocular hypertension

Clinical Data, Inc., today announced that Santen Pharmaceutical Co., Ltd., has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for Clinical Data's highly selective adenosine A2A agonist, ATL313, for the indication of primary open angle glaucoma and ocular hypertension.

From Santen Pharmaceutical Co., Ltd. 23 Dec 2010

Enrollment begins in Phase 2 trial of RegeneRx’s RGN-259 in dry eye associated with graft vs. host disease

RegeneRx Biopharmaceuticals, Inc. announced today that the first patient has been screened and is being enrolled in a Phase 2 clinical trial testing the Company's drug candidate RGN-259 in patients with dry eye associated with graft vs. host disease. The double-blind, placebo-controlled, investigator-sponsored trial is expected to enroll a total of 20 patients over the next several months, with data reported later in 2011. RGN-259 is a sterile, preservative-free topical eye drop formulation of the novel therapeutic peptide Thymosin beta 4, or Tβ4.

23 Dec 2010

OXIS International files patent application to strengthen Ergothioneine intellectual property portfolio

OXIS International, Inc., today announced that is has filed a patent application titled "Methods and Compositions Using Ergothioneine to Treat a Variety of Health Related Factors" with the U.S. Patent and Trademark Office (USPTO).

20 Dec 2010

Positive top-line results from VEGF Trap-Eye Phase 3 studies in macular edema due to CRVO

Regeneron Pharmaceuticals, Inc. and Bayer HealthCare announced positive top-line results for VEGF Trap-Eye (aflibercept ophthalmic solution) in the COPERNICUS study, which is led by Regeneron, the first of two Phase 3 studies in patients with macular edema due to central retinal vein occlusion (CRVO).

20 Dec 2010

Early intervention can improve core symptoms of ASD in young children: Study

In a study recently published in the Journal of Child Psychology and Psychiatry (Epub ahead of print), researchers from the Kennedy Krieger Institute found that early intervention can improve the core symptoms of autism spectrum disorders in very young children.

17 Dec 2010

City Tech Nursing Professor provides community-based care plan to study difference in health outcomes

Patients with diabetes who follow a self-care regimen generally have success in controlling their disease. But what about patients whose other health conditions, such as cognitive impairment and/or depression, create barriers to effective treatment?

17 Dec 2010

Stem cell therapy gives sight to four year old

Izabelle Evans, only four years of age, was born blind but in a medical miracle has been given sight. After a stem cell treatment in China she can see. Her parents James Evans and Hollie McHugh are “over the moon” that their daughter can finally see them. As of now she can see only 3ft away. The treatment that cost the family £50,000.

16 Dec 2010

NextGen Healthcare announces partnership with Wills Eye for meaningful use

NextGen Healthcare Information Systems, a wholly owned subsidiary of Quality Systems, and leading provider of healthcare information systems and connectivity solutions, today announced an agreement with Wills Eye Health System to deploy NextGen® Ambulatory EHR and NextGen® Practice Management.

16 Dec 2010

Early intervention for children with autism improves I.Q., language and social skills

Early intervention for children with autism, as young as 6 months of age, may change the development trajectory for later symptoms of the disorder according to a research project being spearheaded by the MIND Institute at the University of California Davis Medical Center. A recent study published by Pediatrics recorded randomized trials of daily therapy through games and pretend play for children, which demonstrated an improvement in I.Q., language and social skills.

15 Dec 2010

Anoles key to medically applicable regeneration?

Anolis lizards first entered Arizona State University biologist Kenro Kusumi's life in 1980 when, as a member of a junior curator program, he recorded in his field notebook that he had found an Anolis egg on a field trip. Kusumi still has those notes, along with other memorabilia that document the influence that both his early life and more recent experiences have had on his current pursuits in developmental biology.

15 Dec 2010

Survey reveals 40% of consumers prefer to purchase vision care services during weekends, evenings

An independent, national survey reveals 40 percent of consumers prefer to shop for and purchase vision correction services during evenings or weekends.

15 Dec 2010

Alcon board approves merger agreement with Novartis

Alcon, Inc. announced today that its board of directors approved a merger agreement with Novartis AG, whereby Novartis will pay a total merger consideration valued at $168 per share for the Alcon shares it does not currently own. Under the terms of the deal, the merger consideration will be comprised of a combination of Novartis shares and, if necessary, a cash contingent value amount to result in a total value of $168 per share.

15 Dec 2010

World's first remote 3D keyhole surgery to be performed at University of Surrey

Doctors will shortly be performing the world's first remote 3D keyhole surgery during a symposium at the University of Surrey. Keyhole surgery - where doctors operate on organs through a tiny incision - reduces the length of hospital stays and post-operative complications. This also means that patients experience less scarring and pain. 3D keyhole surgery is a state-of-the-art extension of standard keyhole surgery that uses 3D cameras like those used to make the film 'Avatar'. It puts the surgeon right inside the patient's body and significantly improves accuracy.

14 Dec 2010

Marketers must pay $2.1M to refund purchasers of Disney- and Marvel heroes-licensed vitamins

As part of its ongoing efforts to stop bogus health claims, the Federal Trade Commission has reached a settlement requiring major marketers of children's vitamins to stop making false and unproven claims that their supplements promote healthy brain and eye development in children. The companies have agreed to pay $2.1 million to provide refunds to consumers who purchased certain multivitamins in their Disney and Marvel Heroes line.

14 Dec 2010

Grey's Anatomy features patient with von Hippel-Lindau disease

The second episode in a three-part series on Grey's Anatomy features a patient with von Hippel-Lindau disease (VHL). The next new episode in the show is expected to air on January 6. The first episode, "Adrift and at Peace," aired Dec. 2.

14 Dec 2010

Panasonic to manufacture electronic lenses for PixelOptics' electronic focusing eyeglasses

PixelOptics of Roanoke, Virginia USA announced today that Panasonic Healthcare Co., Ltd. of Ehime, Japan will manufacture electronic lenses for PixelOptics' electronic focusing eyeglasses named emPower!™. The emPower! eyeglasses focus faster than the blink of an eye, have no moving parts, and change focus without making a sound. In March of 2010 at Vision Expo East in New York, New York, Pixel and Panasonic announced that they have been working together for the last two plus years to develop and optimize Pixel's electronic lenses.

From PHC Europe B.V. 13 Dec 2010

Santen launches DIQUAS Ophthalmic Solution in Japan

Inspire Pharmaceuticals, Inc. announced that DIQUAS Ophthalmic Solution 3% (diquafosol tetrasodium) received pricing approval and was launched for sale today in Japan by its partner, Santen Pharmaceutical Co., Ltd. Inspire will receive a related milestone payment of $1.25 million in the fourth quarter of 2010 and is also entitled to receive payments based upon a tiered royalty rate on net sales of DIQUAS in Japan, with a minimum rate in the high single digits and a maximum rate in the low double digits.

From Santen Pharmaceutical Co., Ltd. 13 Dec 2010

Eye News and Research

Latest Eye News and Research

Study reports ROP18 protein protects parasite in host cell

Alimera receives FDA CRL for ILUVIEN NDA

Health spending and mandates: What is central to the overhaul's implementation and what is not

Santen files IND for Clinical Data's ATL313 for primary open angle glaucoma and ocular hypertension

Enrollment begins in Phase 2 trial of RegeneRx’s RGN-259 in dry eye associated with graft vs. host disease

OXIS International files patent application to strengthen Ergothioneine intellectual property portfolio

Positive top-line results from VEGF Trap-Eye Phase 3 studies in macular edema due to CRVO

Early intervention can improve core symptoms of ASD in young children: Study

City Tech Nursing Professor provides community-based care plan to study difference in health outcomes

Stem cell therapy gives sight to four year old

NextGen Healthcare announces partnership with Wills Eye for meaningful use

Early intervention for children with autism improves I.Q., language and social skills

Anoles key to medically applicable regeneration?

Survey reveals 40% of consumers prefer to purchase vision care services during weekends, evenings

Alcon board approves merger agreement with Novartis

World's first remote 3D keyhole surgery to be performed at University of Surrey

Marketers must pay $2.1M to refund purchasers of Disney- and Marvel heroes-licensed vitamins

Grey's Anatomy features patient with von Hippel-Lindau disease

Panasonic to manufacture electronic lenses for PixelOptics' electronic focusing eyeglasses

Santen launches DIQUAS Ophthalmic Solution in Japan

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Shaping the future of lab automation through AI and robotics

Eye News and Research

Latest Eye News and Research

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Shaping the future of lab automation through AI and robotics

Newsletters you may be interested in